SCHEMBL3540722

SCHEMBL3540722

CC1CCN(c2cc(N3CCNCC3)ccc2[N+](=O)[O-])CC1

nearest known ligand 0.73

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 15/20 0.73
ALDH1A1 P00352 9/20 0.73
SMN1; SMN2 Q16637 3/20 0.71
MAPK1 P28482 2/20 0.71
CYP1A2 P05177 2/20 0.60
CYP2C19 P33261 2/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
HTR6 P50406 1/20 0.60
RECQL P46063 1/20 0.59
POLB P06746 2/20 0.58
CYP2C9 P11712 2/20 0.58
HTT P42858 1/20 0.58
RAB9A P51151 1/20 0.54
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
NPSR1 Q6W5P4 1/20 0.52
HPGD P15428 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3541105 0.86 ALDH1A1 (0.74) MAPTALDH1A1SMN1; SMN2MAPK1CYP1A2
SCHEMBL31000430 0.86 ALDH1A1 (0.74) MAPTALDH1A1SMN1; SMN2MAPK1CYP1A2
SCHEMBL12684722 0.85 MAPT (0.97) MAPTALDH1A1SMN1; SMN2MAPK1CYP1A2
SCHEMBL9073260 0.85 MAPT (0.97) MAPTALDH1A1SMN1; SMN2MAPK1CYP1A2
SCHEMBL3537665 0.85 MAPT (0.73) MAPTALDH1A1SMN1; SMN2CYP1A2CYP2C19
Hydrochloric Acid SCHEMBL30124765 0.84 MAPT (0.97) MAPTALDH1A1SMN1; SMN2MAPK1CYP1A2
Hydrochloric Acid SCHEMBL22095459 0.84 MAPT (0.97) MAPTALDH1A1SMN1; SMN2MAPK1CYP1A2
SCHEMBL22095062 0.84 MAPT (1.00) MAPTALDH1A1SMN1; SMN2MAPK1CYP1A2
SCHEMBL27691387 0.82 MAPT (0.56) MAPTALDH1A1SMN1; SMN2MAPK1CYP1A2
SCHEMBL28766651 0.81 MAPT (0.55) MAPTALDH1A1SMN1; SMN2MAPK1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP disclosed
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP disclosed
CN-101084208-A Aromatic amides as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2007-12-05 CN disclosed
EP-1807407-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-18 EP disclosed
US-20060100201-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-11 US disclosed
WO-2006047504-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100201-A1 Inhibitors of c-fms kinase MUSK, FLT3, FES MAPT 159/4885ALDH1A1 4796/4885SMN1; SMN2 1548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.